Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the ...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug ...

We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In this article, we are going to ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

On Tuesday, Pfizer Inc (PFE) stock saw a decline, ending the day at $25.77 which represents a decrease of $-0.40 or -1.53% from the prior close of $26.17. The stock opened at $26.16 and touched a low ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...

Pfizer may not be able to recover the $75.2 million that was left from a Securities and Exchange Commission insider trading ...